Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$342.17 - $402.31 $88,279 - $103,795
-258 Reduced 22.05%
912 $345,000
Q3 2022

Nov 14, 2022

BUY
$343.2 - $395.75 $401,544 - $463,027
1,170 New
1,170 $413,000
Q1 2022

May 12, 2022

SELL
$254.45 - $351.06 $147,072 - $202,912
-578 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$272.01 - $353.03 $157,221 - $204,051
578 New
578 $202,000
Q3 2019

Nov 12, 2019

SELL
$113.31 - $150.51 $250,415 - $332,627
-2,210 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$115.0 - $141.58 $254,150 - $312,891
2,210 New
2,210 $313,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.9B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Blueshift Asset Management, LLC Portfolio

Follow Blueshift Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blueshift Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Blueshift Asset Management, LLC with notifications on news.